Giuliani Fabrizio, Metz Luanne M, Wilson Tammy, Fan Yan, Bar-Or Amit, Yong V Wee
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
J Neuroimmunol. 2005 Jan;158(1-2):213-21. doi: 10.1016/j.jneuroim.2004.09.006.
There have been significant advances in the treatment of multiple sclerosis (MS) in recent years, but further improvement in therapy is required as not all patients have responded optimally. An approach to enhancing MS treatment is to combine drugs that impact on different aspects of the disease process. We have described that the tetracycline derivative, minocycline, attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a model of MS. Here, we have evaluated the combination of minocycline and glatiramer acetate (GA), a current therapy in MS, on the course of EAE in mice. This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination.
近年来，多发性硬化症（MS）的治疗取得了重大进展，但由于并非所有患者都获得了最佳疗效，因此仍需要进一步改进治疗方法。一种增强MS治疗效果的方法是联合使用作用于疾病进程不同方面的药物。我们已经描述过，四环素衍生物米诺环素可减轻实验性自身免疫性脑脊髓炎（EAE，一种MS模型）的严重程度。在此，我们评估了米诺环素与MS目前的一种治疗药物醋酸格拉替雷（GA）联合使用对小鼠EAE病程的影响。这种联合用药显著降低了疾病严重程度和疾病负担，减轻了炎症、轴突损失和脱髓鞘。
